Evrard Bertrand, Cosme Justine, Raveau Marion, Junda Maud, Michaud Elodie, Bonnet Benjamin
Service d'Immunologie, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Laboratoire d'Immunologie, ECREIN, UMR 1019 Unité de Nutrition Humaine, Faculté de Médecine de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France.
Front Allergy. 2022 May 18;3:908435. doi: 10.3389/falgy.2022.908435. eCollection 2022.
There are two major clinically described forms of IgE-dependent soy allergy: (i) a primary dietary form, linked to sensitization against soy storage proteins Gly m 5 and Glym 6, and (ii) a form included in birch-soy syndromes linked to Gly m 4, a PR-10-like allergen. This second form sometimes causes severe systemic reactions, even anaphylaxis, especially on consuming certain forms of soy such as soymilks or smoothies. Skin prick tests and specific IgE assays against soy whole extracts lack sensitivity. Assays of anti-Gly m 4, Gly m 5 and Gly m 6 specific IgEs have been developed to overcome this obstacle, but they unfortunately lack specificity, especially for anti-Gly m 4. We hypothesized that the basophil activation test (BAT) using molecular soy allergens Gly m 4, Gly m 5 and Gly m 6 would both remedy the lack of sensitivity of other tests and offer, through its mechanistic contribution, greater specificity than the assay of anti-Gly m 4 specific IgEs. This would enable the two types of soy allergy to be separately identified. In a characteristic clinical example of PR-10-induced anaphylactic reaction after consuming soymilk, we report preliminary results of Gly m 4-exclusive positivity of BAT supporting our hypothesis. It will be necessary to confirm these results on more patients in subsequent studies, and to specify the place of the BAT in an overall diagnostic strategy. Meanwhile, soy BAT using molecular allergens is a promising diagnostic tool for soy allergy and probably also for follow-up in specific immunotherapies.
临床上描述的IgE依赖型大豆过敏主要有两种形式:(i)原发性饮食型,与对大豆储存蛋白Gly m 5和Gly m 6的致敏有关;(ii)桦树-大豆综合征中的一种形式,与类PR-10过敏原Gly m 4有关。后一种形式有时会引起严重的全身反应,甚至过敏反应,尤其是在食用某些形式的大豆(如豆浆或奶昔)时。针对大豆全提取物的皮肤点刺试验和特异性IgE检测缺乏敏感性。已开发出抗Gly m 4、Gly m 5和Gly m 6特异性IgE的检测方法来克服这一障碍,但不幸的是它们缺乏特异性,尤其是抗Gly m 4的检测。我们假设,使用分子大豆过敏原Gly m 4、Gly m 5和Gly m 6的嗜碱性粒细胞活化试验(BAT)既能弥补其他检测方法的敏感性不足,又能通过其机制作用提供比抗Gly m 4特异性IgE检测更高的特异性。这将能够分别识别两种类型的大豆过敏。在一个饮用豆浆后发生PR-10诱导的过敏反应的典型临床实例中,我们报告了BAT仅对Gly m 4呈阳性的初步结果,支持了我们的假设。在后续研究中需要在更多患者身上证实这些结果,并明确BAT在整体诊断策略中的地位。同时,使用分子过敏原的大豆BAT是一种有前景的大豆过敏诊断工具,可能对特异性免疫疗法的随访也有帮助。